Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
January 06 2021 - 8:00AM
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative, disease-modifying therapies for neurodegenerative
diseases, today announced that Paulash Mohsen, Chief Business
Officer, will present at the H.C. Wainwright Virtual BioConnect
Conference.
The presentation will be available on-demand via the conference
portal and through the Company's website at yumanity.com/events
beginning January 11, 2021 starting at 6:00am EST.
About Yumanity TherapeuticsYumanity
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to accelerating the revolution in the treatment of
neurodegenerative diseases through its scientific foundation and
drug discovery platform. The Company’s most advanced product
candidate, YTX-7739, is currently in Phase 1 clinical development
for Parkinson’s disease. Yumanity’s drug discovery platform is
designed to enable the Company to rapidly screen for potential
disease-modifying therapies by overcoming toxicity of misfolded
proteins in neurogenerative diseases. Yumanity’s pipeline consists
of additional programs focused on dementia with Lewy bodies,
multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou
Gehrig’s disease), frontotemporal lobar dementia (FTLD), and
Alzheimer’s disease.
For more information, please visit www.yumanity.com.
ContactsInvestors:Burns
McClellan, Inc.John Grimaldijgrimaldi@burnsmc.com (212)
213-0006
Media:Burns McClellan, Inc.Ryo Imai / Robert
Flamm, Ph.D.rimai@burnsmc.com / rflamm@burnsmc.com (212)
213-0006
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jul 2023 to Jul 2024